GLP1R and type 2 diabetes mellitus: In multivariable regression, baseline dapagliflozin use was most clearly associated with a more favorable change in SDNN.<h4>Conclusion</h4>In patients with T2DM, dapagliflozin use was associated with a decline in HRV during GLP-1 RA therapy; these findings are hypothesis-generating and require confirmation in larger prospective studies.